Welcome to our dedicated page for Rocket Pharmaceu SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rocket Pharmaceuticals, Inc. (RCKT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, late-stage biotechnology company, Rocket uses SEC reports to communicate material information about its gene therapy pipeline, financial condition, governance and significant corporate events.
Investors can use this page to locate current reports on Form 8-K, which Rocket files to describe events such as financial results, strategic corporate reorganization and pipeline prioritization, clinical trial developments and regulatory milestones. Recent 8-K filings referenced in available information include announcements of quarterly financial results, FDA acceptance of the resubmitted Biologics License Application (BLA) for KRESLADI in severe leukocyte adhesion deficiency-I (LAD-I), lifting of the clinical hold on the pivotal Phase 2 trial of RP-A501 for Danon disease, and leadership or board changes.
In addition to 8-Ks, users can access Rocket’s periodic reports on Forms 10-K and 10-Q, which provide more detailed discussions of its AAV and lentiviral gene therapy programs, risk factors and financial statements. These filings help explain how Rocket is prioritizing its AAV cardiovascular platform—covering Danon disease, PKP2-arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy—while advancing regulatory activities for KRESLADI and pausing additional internal investment in certain other programs.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, such as clinical and regulatory updates, restructuring plans, and changes in executive leadership. Real-time EDGAR updates allow users to see new Rocket filings as they are posted, while Form 4 insider transaction data and proxy materials can be reviewed to understand equity awards, inducement grants and governance practices. This page serves as a focused entry point for analyzing how Rocket’s SEC disclosures relate to the development and potential commercialization of its rare disease gene therapy portfolio.
Rocket Pharmaceuticals Inc reported an amendment to institutional holdings showing 0 shares beneficially owned by The Vanguard Group after an internal realignment. The filing states that, following the realignment described in January 12, 2026, certain Vanguard subsidiaries will report holdings separately.
The Schedule 13G/A lists Amount beneficially owned: 0 and Percent of class: 0%. The filing is signed by Ashley Grim on March 27, 2026.
Rocket Pharmaceuticals announced that the FDA has granted accelerated approval for KRESLADI, an autologous hematopoietic stem cell gene therapy for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) who lack a matched sibling donor for transplant. The approval is based on increased neutrophil CD18 and CD11a surface expression, and continued approval may depend on confirming clinical benefit in ongoing studies and a post-marketing registry.
With KRESLADI’s approval, Rocket received a Rare Pediatric Disease Priority Review Voucher and plans to evaluate strategic options to monetize this voucher to enhance financial flexibility and shareholder value. The company highlighted that KRESLADI is the first FDA‑approved gene therapy for children with severe LAD-I, a life‑threatening ultra‑rare immunodeficiency characterized by recurrent serious infections and high early‑childhood mortality without treatment.
Rocket Pharmaceuticals, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held solely by remote communication at www.virtualshareholdermeeting.com/RCKT2026 on May 20, 2026. The Board recommends votes FOR election of seven director nominees, ratification of EisnerAmper LLP as independent auditors, approval of the non-binding advisory vote on named executive officer compensation, and approval of a proposed stock option exchange program.
Shares outstanding for voting purposes were 109,122,837 as of March 24, 2026. The proxy materials and the 2025 Annual Report on Form 10-K are available at www.proxyvote.com and on the company website; preliminary results will be announced at the meeting and final results filed on Form 8-K.
Rocket Pharmaceuticals entered into a new sales agreement with Cantor Fitzgerald & Co. to establish an at-the-market stock offering program. Under this arrangement, the company may, at its discretion, sell shares of its common stock with an aggregate offering price of up to $100,000,000 through Cantor as sales agent.
The shares will be issued under an existing shelf registration statement on Form S-3, supported by a prospectus supplement filed the same day. Cantor will sell the shares in transactions deemed at-the-market on Nasdaq, earning a cash commission of up to 3.0% of gross proceeds. Rocket can suspend or terminate sales at any time, and the program ends once all shares are sold or the agreement is otherwise terminated.
In connection with this new arrangement, Rocket terminated its prior at-the-market sales agreement with Cowen and Company, LLC. Legal opinions and the full sales agreement are filed as exhibits, providing the formal framework for potential future equity issuance.
Rocket Pharmaceuticals has filed a prospectus supplement to sell up to $100,000,000 of common stock in an at-the-market offering. The company may sell shares from time to time through Cantor Fitzgerald & Co. acting as sales agent under a sales agreement that replaces a prior agreement with TD Securities.
The supplement bases its illustrative example on selling 19,569,471 shares at $5.11 per share and states shares outstanding were 108,319,783 as of December 31, 2025. Net proceeds are intended for general corporate purposes and working capital; commissions to Cantor are up to 3% of gross proceeds.
Rocket Pharmaceuticals, Inc. has filed a shelf registration on Form S-3 to offer, from time to time, up to $400,000,000 of common stock, preferred stock, debt securities, warrants and/or units, in one or more offerings, as set forth in prospectus supplements.
The prospectus states the offering is a shelf registration that permits multiple issuances in amounts, at prices and on terms to be determined at the time of each offering. Authorized capital stock is 180,000,000 shares of common stock; shares outstanding were 108,569,143 as of March 2, 2026.
Rocket Pharmaceuticals reported fourth-quarter 2025 net loss of $42,538, improving from $60,327 a year earlier. Full-year 2025 net loss was $223,123, compared with $258,746 in 2024, with net loss per share of $2.01 versus $2.73.
Total operating expenses for 2025 were $231,747, down from $273,205 in 2024, reflecting lower research and development and general and administrative spending and recorded restructuring charges of $3,231. Cash, cash equivalents and investments were $188,929 at December 31, 2025, versus $372,336 a year earlier, which the company says supports an operational runway into the second quarter of 2027.
Operationally, Rocket highlighted progress across its cardiovascular gene therapy programs. The pivotal Phase 2 trial of RP‑A501 for Danon disease is expected to resume in the first half of 2026, the KRESLADI™ BLA for severe LAD‑I has a March 28, 2026 PDUFA date, and first dosing in a Phase 1 study of RP‑A701 for BAG3‑related dilated cardiomyopathy is anticipated in mid‑2026.
Rocket Pharmaceuticals is a late-stage biotech company developing gene therapies for rare, often fatal genetic diseases, with a strategic focus on inherited cardiomyopathies. It runs both AAV and lentiviral platforms and operates a large cGMP manufacturing facility in Cranbury, New Jersey.
In 2025 Rocket implemented a corporate reorganization, including a workforce reduction of about 30% and cost-saving initiatives expected to lower 12‑month operating expenses by roughly 25%, to extend its cash runway and concentrate resources on its AAV cardiovascular pipeline. Development of Fanconi anemia and pyruvate kinase deficiency programs is being de‑prioritized while the company explores partnerships.
Lead programs include RP‑A501 for Danon disease, where positive long‑term Phase 1 data supported a pivotal Phase 2 trial that was temporarily paused after two serious adverse events, including one death, then allowed to resume at a lower dose with added safeguards. RP‑A601 for PKP2‑related arrhythmogenic cardiomyopathy has early Phase 1 data showing tolerability and increased PKP2 expression, and RP‑A701 for BAG3‑related dilated cardiomyopathy entered Phase 1 after FDA IND clearance and Fast Track designation.
In hematology, ex vivo gene therapy KRESLADI for severe LAD‑I has published long‑term data and a resubmitted BLA with a new PDUFA date of March 28, 2026. Across programs, Rocket highlights extensive regulatory designations, complex licensing arrangements, and a wide array of risks, including ongoing losses, financing needs, clinical and regulatory uncertainty, manufacturing and data‑privacy obligations, intense competition, and protection of its intellectual property.